: National Coverage Determination (NCD 110.24): Chimeric Antigen Receptor (CAR) T-cell Therapy
The purpose of this Change Request (CR) is to provide updated instructions on how to process claims in the Part B physician office and independent clinics for Chimeric Antigen Receptor (CAR) T Cell Therapy..
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: December 30, 2022
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.